Eli Lilly’s Retatrutide Cuts Body Weight by 17%, Lowers HbA1C in Phase 3 Diabetes Trial
Eli Lilly's diabetes drug Retatrutide caused up to 17% body weight loss and nearly 2% HbA1C reduction in a Phase 3 trial. These results suggest a major advancement in diabetes treatment by addressing both blood sugar and obesity effectively.
· 77d ago
